https://www.cancernetwork.com/view/ian-d-davis-mbbs-phd-reviews-interesting-data-from-therap-trial-of-177lu-psma-617-in-mcrpc-at-2022-asco
0
0
8/29/22 at 12:02pm
Organization
Cancernetwork.com
47 words
0
Comments
Ian D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.
You are the first to view
Create an account
or login to join the discussion